miReven
miReven is a biopharmaceutical company focused on developing mRx-7 as a new cancer therapy. The world of RNA-based therapeutics is an entirely new clinical treatment
Our Science
mRx-7 is a synthetic small double stranded RNA (dsRNA) chemically modified mimic of microRNA-7 (miR-7) that we have designed, which is a potent inhibitor of…
Investors
miReven welcomes new partnerships Please contact us for information about investing in our company
microRNA replacement therapy
microRNAs are tiny molecules that are encoded in the DNA within our cells. They are responsible for controlling expression of genes that dictate how the cell behaves, including deciding when to divide or move. In some cancers the amount of
A novel approach for treating cancers
Recent News
Prof Peter Leedman presents recent results at FNA meeting
Prof Peter Leedman presented the latest promising results of mRx-7 at the Functional Nucleic Acid (FNA) Meeting, held at Murdoch University in Perth, Western Australia
miReven scientists evaluate microRNA-7 delivery
miReven scientists evaluate microRNA-7 delivery in preclinical models and methods for quantitation and publish in Methods of Molecular Biology 2018
miReven scientists publish in Hepatology
miReven scientists publish paper in prestigious journal Hepatology identifying new pathways that mediate resistance to sorafenib and showing that microRNA-7 can overcome therapeutic resistance in